NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-10-23 10:07இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Cyient DLM Reports Record Order Book of ₹2,813 Cr in Q2 FY27 Earnings Call
Cyient DLM released the transcript of its Q2 FY27 earnings conference call held on October 15, 2026. Management highlighted an all-time high order backlog of ₹2,813 crore (over 2x TTM revenue) with an active sales pipeline exceeding $1 billion. Revenue for the quarter grew over 26% YoY, while H1 FY27 recorded more than 30% YoY growth. Near-term margins saw slight pressure due to uncapitalized R&D investments in build-to-spec products and sales team expansion, but management expects margins to expand back past 10% in FY28 as backlog execution ramps up.
உச்சம் நம்பிக்கை
என்ன மாறியதுCyient DLM filed the detailed earnings call transcript for Q2 FY27, detailing order book expansion, growth across aerospace/industrial sectors, and upfront P&L investments.
ஏன் இது முக்கியம்The order book of ₹2,813 crore provides exceptional revenue visibility representing ~207% of TTM revenue (₹1,357 crore), affirming strong high-reliability EMS demand despite near-term investment drags on margins.
Order backlog: ₹2,813 கோடிOrder backlog vs TTM revenue: ~207%Active sales pipeline: in excess of $1 billionBook-to-bill ratio (Q2): over 1.6xAverage execution timeline: 18 to 24 months
📅 குறுகிய காலம்The transcript reinforces strong demand and sustained momentum; near-term stock reaction may reflect steady operational performance offset by upfront P&L expenses on product development.
📈 நீண்ட காலம்Pivot from build-to-print toward build-to-spec (B2S) and higher-margin sectors like AI data center infrastructure and semiconductor capital equipment could structurally enhance margins beyond 10%.
⚠ அபாய எச்சரிக்கைகள்
Client concentration risk persists historically in top customers
Memory component supply chain lead-times and shortages
P&L margin drag from front-loaded investments and uncapitalized R&D
👀 கவனிக்க வேண்டியவை
Track conversion pace of the ₹2,813 crore order book into billable revenue over the 18-24 month execution cycle and monitor operating margin recovery toward the targeted 10%+ in coming quarters.
Cyient DLM Q2 FY27: Revenue Up 26.5% to ₹393.1 Cr, Order Book Reaches Record ₹2,813.7 Cr
Cyient DLM reported a 26.5% YoY increase in Q2 FY27 revenue to ₹393.1 crore, while EBITDA grew 9.5% YoY to ₹34.2 crore with margins at 8.7%. Normalized PAT rose 25.8% YoY to ₹15.82 crore, though reported PAT was ₹34.0 crore boosted by an ₹18.2 crore earnout reversal one-off gain. The company's order book hit an all-time high of ₹2,813.7 crore, up ₹214.8 crore QoQ, providing strong visibility at over 2x TTM revenue (₹1,357 crore). Free cash flow stood positive at ₹17.2 crore during the quarter.
உச்சம் நம்பிக்கை
என்ன மாறியதுCyient DLM published its Q2 FY27 earnings showing 26.5% revenue growth and completed the integration of US-based Altek Electronics (now Cyient DLM Electronics Inc.).
ஏன் இது முக்கியம்The order book reaching ₹2,813.7 crore offers robust multi-year revenue visibility, though EBITDA margin of 8.7% reflects ongoing pressure relative to peers and long-term targets.
📅 குறுகிய காலம்Market sentiment should be supported by strong top-line growth and a record order book, though investors will adjust for the ₹18.2 crore one-off earnout gain in reported PAT.
📈 நீண்ட காலம்Integration of Altek Electronics and expansion into B2S capabilities, semiconductors, and AI hardware enhance structural positioning across global aerospace and defense supply chains.
⚠ அபாய எச்சரிக்கைகள்
One-off earnout reversal of ₹18.2 crore inflating reported PAT
Operating margin pressure with EBITDA margin at 8.7%
High customer concentration historically
👀 கவனிக்க வேண்டியவை
Track the execution pace of the record ₹2,813.7 crore order book and monitor whether operating margins expand toward double digits without reliance on one-off adjustments.
1.5x Book-to-Bill Ratio and Record Order Book Highlighted in Q1 FY27 Earnings Call
Cyient DLM reported a strong start to FY27, achieving its highest-ever order book and a robust book-to-bill ratio of 1.5x. The company has successfully maintained double-digit EBITDA margins for four consecutive quarters, reflecting improved operational efficiency and a shift toward higher-margin contracts. Management is aggressively targeting expansion into AI infrastructure, robotics, and semiconductor equipment, leveraging its recent Rs 248 Cr acquisition of Altek Electronics in the US. With current capacity capable of supporting 1.75x to 2x current revenue, the company is well-positioned for its next growth phase.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from a turnaround phase to a sustained growth phase with a record order book and stabilized double-digit margins.
ஏன் இது முக்கியம்The high book-to-bill ratio and expansion into high-complexity segments like AI and Defense reduce the company's exposure to low-margin commodity electronics and provide long-term revenue visibility.
Book-to-bill ratio: 1.5xCapacity headroom: 1.75x to 2x revenueAltek Acquisition Value: Rs 248 கோடிOrder Book (June 2024 baseline): Rs 2,127 கோடிTTM வருவாய்: Rs 1,261 கோடி
📅 குறுகிய காலம்Positive sentiment is expected as the market reacts to the record order book and consistent margin performance.
📈 நீண்ட காலம்Structural growth is supported by the 'China Plus One' strategy and the company's move into high-value 'design-led manufacturing' for AI and Defense sectors.
⚠ அபாய எச்சரிக்கைகள்
High client concentration (top 5 customers contribute 68% of revenue)
Geopolitical disruptions in the Middle East affecting supply chains
👀 கவனிக்க வேண்டியவை
Monitor the execution of the record order book and the ramp-up of the new AI and robotics product lines over the next 2-3 quarters to see if margins remain above the 10% threshold.
34.3% Revenue Growth and Record Order Book of ₹2,598.9 Cr in Q1FY27
Cyient DLM reported a strong start to FY27 with Q1 revenue growing 34.3% YoY to ₹373.8 crore. Profitability saw a significant surge as PAT more than doubled (up 118.2% YoY) to ₹16.3 crore, driven by EBITDA margins sustaining at 10.5%. The company achieved its highest-ever order book of ₹2,598.9 crore, which is approximately 2.06x its TTM revenue, providing strong future visibility. However, Free Cash Flow remained negative at ₹-17.1 crore due to inventory build-up for long-term programs.
உச்சம் நம்பிக்கை
என்ன மாறியதுCyient DLM has reached a record high order book and sustained double-digit EBITDA margins for a full year, indicating a successful shift toward higher-margin contracts and better operational scale.
ஏன் இது முக்கியம்The record order book (over 200% of TTM revenue) provides significant revenue visibility for the next 18-24 months. The doubling of PAT suggests that the company is successfully absorbing fixed costs as it scales toward its ₹1,500 Cr+ revenue target.
📅 குறுகிய காலம்The stock is likely to react positively to the strong PAT growth and the record order book, which exceeds market expectations for visibility.
📈 நீண்ட காலம்The structural shift toward 'Design-Led Manufacturing' and expansion into AI/Robotics, combined with a massive order backlog, positions the company for sustained 30-40% growth as previously guided.
⚠ அபாய எச்சரிக்கைகள்
Negative free cash flow due to inventory build-up
High client concentration (top 5 customers contribute 68% of revenue)
Potential supply chain risks for critical components
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution timeline of the ₹2,598.9 crore order book and the company's ability to transition negative free cash flow into positive territory as inventory is utilized. Watch for updates on the new AI infrastructure and robotics segments mentioned by management.
Cyient DLM Q1 FY27: Net Profit Jumps 118% YoY to ₹16.3 Cr; Revenue Up 34% YoY
Cyient DLM reported a strong year-on-year performance for the quarter ended June 30, 2026, with consolidated revenue growing 34.2% to ₹373.8 Cr. Net profit more than doubled YoY to ₹16.3 Cr from ₹7.46 Cr, although it declined 27.4% sequentially from the March 2026 quarter (₹22.4 Cr). The company's employee benefit expenses rose 11.5% sequentially to ₹64.4 Cr, impacting margins. Additionally, Dr. Ganesh Natarajan was appointed to the board of the material US subsidiary, Cyient DLM Inc.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company released its Q1 FY27 financial results, showing significant year-on-year growth in both top and bottom lines, alongside a key board appointment for its US subsidiary.
ஏன் இது முக்கியம்The results validate the company's 30-40% growth guidance and its ability to scale operations, though the sequential profit dip highlights ongoing margin pressure from operating expenses.
📅 குறுகிய காலம்The market is likely to react positively to the strong YoY growth figures, though the sequential decline in profit and rising costs may lead to some consolidation.
📈 நீண்ட காலம்The company remains on a high-growth trajectory supported by a large order book and US expansion; long-term value depends on improving operating margins toward the double-digit range.
⚠ அபாய எச்சரிக்கைகள்
Sequential decline in net profit
Rising employee benefit expenses
High client concentration (top 5 customers contribute 68% of revenue)
👀 கவனிக்க வேண்டியவை
Monitor the operating margin trajectory in upcoming quarters to see if the company can offset rising employee costs through the execution of its high-margin 'design-to-production' contracts.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Cyient DLM FY26 Report: Order Book Hits ₹24.2 Billion with 1.46x Book-to-Bill Ratio
Cyient DLM is undergoing a strategic transformation from a pure-play manufacturer to a design-led partner, evidenced by a strong book-to-bill ratio of 1.46x and an order book of ₹24.2 billion. The company has successfully diversified its portfolio, reducing Aerospace & Defence exposure from 73% to 52% while scaling Industrial and Medical segments to 27% and 19% respectively. A key focus is the shift toward 'Build-to-Spec' (B2S) projects, which currently contribute 6% of revenue but are targeted for double-digit growth in FY27 to drive higher margins.
முக்கிய அம்சங்கள்
Order book reached a historic high of ₹24.2 billion as of March 31, 2026, with a 1.46x book-to-bill ratio.Significant diversification achieved with non-Aerospace & Defence segments now making up 36% of the order book.Targeting double-digit revenue from high-margin 'Build-to-Spec' (B2S) engagements in FY27, up from 6% in FY26.Strategic expansion through the Altek Electronics acquisition in the US and land procurement in Mysore to scale capacity.Secured long-term annuity contracts, including a 9-year lifecycle engagement for a Japanese eVTOL project.
👀 கவனிக்க வேண்டியவை
Investors should view the diversification and shift toward design-led manufacturing as a long-term margin catalyst. The strong order book provides high revenue visibility, making the stock a strong candidate for accumulation on dips.
Cyient DLM Appoints Ramakanth Alapati as President & Chief Strategy and Growth Officer
Cyient DLM has appointed Ramakanth Alapati as President & Chief Strategy and Growth Officer to spearhead its global expansion and strategic initiatives. Based in Dallas, USA, Alapati brings over 20 years of experience in advanced electronics manufacturing and high-precision packaging. His primary focus will be on driving growth in high-potential sectors such as AI, data centers, and next-generation computing. This leadership addition is intended to strengthen the company's global customer pipeline and scale its design-led manufacturing capabilities.
முக்கிய அம்சங்கள்
Ramakanth Alapati appointed as President & Chief Strategy and Growth Officer.Brings over 20 years of experience in electronics manufacturing and deep-tech environments.Strategic focus on high-growth sectors including AI, data centers, and next-gen computing.Based in Dallas, USA, to drive international customer acquisition and global presence.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step toward global scaling; monitor for new contract wins in the AI and data center segments as a result of this leadership change.
Cyient DLM Reports Strong FY26 with $208M Order Intake and 10%+ EBITDA Margins
Cyient DLM reported a robust performance for FY26, achieving its highest-ever order backlog with a book-to-bill ratio of 1.5x. The company secured a total order intake exceeding $208 million during the year, driven by strong demand in Aerospace, Defense, and Automotive sectors. For the first time, EBITDA margins sustained above 10% for the full year across all operations, including the U.S. and India. Management remains optimistic for FY27, focusing on high-value 'build-to-spec' engagements and expansion into AI infrastructure and semiconductor supply chains.
முக்கிய அம்சங்கள்
Achieved a record order intake of over $208 million in FY26 with a book-to-bill ratio of 1.5x.Sustained EBITDA margins at 10% plus for the full year across the entire global portfolio.Successfully commenced series production for a semiconductor mission supply partner and new automotive lines.Exports continue to drive the business, accounting for over 60% of total revenue.Strategic shift towards 'build-to-spec' models to capture higher-value life cycle management opportunities.
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution of the record order backlog which provides high revenue visibility for FY27. The company's successful margin expansion to double digits and entry into semiconductor supply chains are significant long-term growth catalysts.
Cyient DLM FY26 Results: Order Book Hits Record ₹2,416 Cr Despite 17% Revenue Decline
Cyient DLM reported a challenging FY26 with annual revenue declining 17% YoY to ₹1,261.5 crores, though Q4 showed a strong sequential recovery of 21.7% QoQ. Despite top-line pressure, the company maintained double-digit EBITDA margins at 10.3% for the full year, an improvement of 78 bps YoY. The most significant positive is the record order book of ₹2,416.6 crores and a robust book-to-bill ratio of 1.5, indicating strong future revenue visibility. Profitability was supported by reduced finance costs and operational efficiencies, even as normalized PAT saw a slight decline.
முக்கிய அம்சங்கள்
FY26 Revenue fell 17% YoY to ₹1,261.5 Cr, but Q4 Revenue grew 21.7% QoQ to ₹369.1 CrOrder Book reached a record high of ₹2,416.6 Cr with a strong Book-to-Bill ratio of 1.5 for the yearNormalized FY26 EBITDA margin improved by 78 bps to 10.3%, totaling ₹130.2 CrReported PAT for FY26 stood at ₹73.3 Cr, aided by one-off income in Q2Industrial and Medical segments contributed 46% of Q4 order intake, showing successful diversification
👀 கவனிக்க வேண்டியவை
Investors should monitor the conversion of the record order book into revenue in FY27 to confirm a growth turnaround. While the revenue decline is a concern, the margin expansion and strong order pipeline suggest long-term resilience.
Cyient DLM Q4 FY26: Record Order Book of ₹24,166 Mn Despite 13.8% Revenue Decline
Cyient DLM reported a contraction in Q4 FY26 financials with revenue at ₹3,691 Mn (down 13.8% YoY) and PAT at ₹224 Mn (down 27.7% YoY), primarily due to the completion of large defense orders in the previous fiscal year. However, the company achieved a record-high order book of ₹24,166 Mn, reflecting a 15% QoQ growth and a strong book-to-bill ratio of 1.5x for the full year. Normalized EBITDA margins for FY26 improved to 10.3% from 9.6% YoY, driven by a better product mix and cost controls. The company is successfully diversifying, having started series production for automotive and semiconductor equipment manufacturing accounts.
முக்கிய அம்சங்கள்
Order book reached a record ₹24,166 Mn, growing 15% QoQ with a sustained book-to-bill ratio of 1.2 in Q4.Q4 FY26 Revenue and PAT declined YoY by 13.8% and 27.7% respectively, following the completion of major A&D contracts.Normalized FY26 EBITDA margin improved by 77 bps to 10.3%, despite a 17% decline in annual revenue.Finance costs for Q4 fell by 34.4% YoY to ₹56 Mn due to lower interest rates and reduced working capital borrowings.Achieved key milestones in new segments, including IATF certification for Automotive and series production for Semiconductor equipment.
👀 கவனிக்க வேண்டியவை
Investors should look past the temporary YoY revenue dip and focus on the record order book which provides strong visibility for FY27. The successful entry into Automotive and Semiconductor sectors suggests a positive shift in the revenue mix toward high-growth industries.
Cyient DLM Shareholders Approve Variation in IPO Proceeds Utilization with 99.99% Majority
Cyient DLM shareholders have passed a special resolution to vary the objects and terms of utilization of the company's Initial Public Offering (IPO) proceeds. The resolution also includes an extension of the time limit for utilizing these funds, providing the company with greater operational flexibility. The proposal received overwhelming support, with 99.99% of the total votes cast in favor. This approval allows the management to reallocate capital or adjust timelines based on current business requirements and market conditions.
முக்கிய அம்சங்கள்
Special resolution passed to vary IPO objects and extend the utilization timeline for proceeds.The resolution received 99.9967% approval, with 63,704,092 votes in favor and only 2,104 against.100% of the promoter group (41,366,502 votes) and 100% of public institutions (22,290,857 votes) supported the move.The voting process was conducted via remote e-voting from February 7 to March 8, 2026.A total of 63.7 million valid votes were cast out of a shareholder base of 104,162.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's future disclosures to understand the specific changes in how the IPO funds will now be deployed. The near-unanimous institutional support suggests confidence in the management's revised capital allocation strategy.
Cyient DLM to reallocate ₹36.85 crore of IPO proceeds to working capital
Cyient DLM is seeking shareholder approval via a postal ballot to modify the utilization of its IPO proceeds. The company proposes to reallocate ₹36.85 crore originally earmarked for Capital Expenditure to meet incremental Working Capital requirements. Additionally, the timeline for the utilization of these funds has been extended to Fiscal Year 2026-27. This move indicates a strategic shift toward prioritizing operational liquidity over immediate fixed asset investments.
முக்கிய அம்சங்கள்
Reallocation of ₹36.85 crore from Capital Expenditure to Working Capital requirementsRevised Working Capital allocation increased to ₹327.94 crore from the original ₹291.09 croreCapital Expenditure budget significantly reduced to ₹6.72 crore following the transferUtilization timeline for remaining IPO proceeds extended through Fiscal Year 2026-27General Corporate Purposes budget increased by ₹4.20 crore due to lower-than-expected IPO issue expenses
👀 கவனிக்க வேண்டியவை
Investors should evaluate whether the shift toward working capital reflects higher inventory requirements or slower-than-expected execution of capital projects. Monitor the upcoming voting results and management's commentary on the revised growth timeline.
Cyient DLM Q3 FY26: Strong Order Intake of ₹387 Cr and 1.3 Book-to-Bill Ratio
Cyient DLM reported a robust order intake of ₹387 crores in Q3 FY26, achieving a book-to-bill ratio of 1.3 for the quarter and 1.56 YTD. While revenue was soft due to holiday-related push-outs and tariff uncertainties, management expects these shipments to recover in Q4. The company maintained double-digit EBITDA margins, though results were impacted by one-time labor code adjustments and aborted M&A-related expenses. Strategic focus remains on high-margin Build-to-Spec (B2S) programs and expansion into European and defense markets.
முக்கிய அம்சங்கள்
Reported a healthy order intake of ₹387 crores with a book-to-bill ratio of 1.3 for the quarter.Year-to-date (YTD) book-to-bill ratio stands strong at 1.56, providing high revenue visibility for coming quarters.Added 2 new strategic logos in the medical and industrial sectors and commenced revenue from B2S programs.EBITDA margins were impacted by one-time costs related to a new labor code and expenses from a non-materialized M&A deal.Management noted revenue softness was temporary, driven by customer wait-and-watch modes regarding global tariff uncertainties.
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution of the ₹387 crore order book in Q4 to confirm that the Q3 revenue softness was indeed temporary. The increasing mix of Build-to-Spec (B2S) and defense contracts suggests long-term margin expansion potential.
Cyient DLM Q3 FY26: Revenue Drops 31.7% YoY to ₹3,033 Mn; EBITDA Margins Expand to 10.2%
Cyient DLM reported a 31.7% YoY decline in revenue to ₹3,033 million for Q3 FY26, primarily due to the completion of a large defense order in the previous fiscal year. Despite the revenue contraction, normalized EBITDA margins improved significantly by 207 bps to 10.2%, demonstrating operational resilience and a better product mix. The order backlog remains robust at ₹23,494 million, bolstered by a strong quarterly order intake of ₹3,871 million. The company is actively diversifying its portfolio, adding new logos in the Medical and Industrial sectors and increasing its Box Build revenue share to 31%.
முக்கிய அம்சங்கள்
Revenue decreased 31.7% YoY to ₹3,033 Mn due to a high base effect from a large order completion in FY25.Normalized EBITDA margin expanded by 207 bps YoY to 10.2%, reflecting improved efficiency and revenue quality.Order backlog stands at a healthy ₹23,494 Mn with a strong quarterly intake of ₹3,871 Mn.Box Build share of revenue increased to 31% compared to 23% in Q3 FY25, indicating a shift towards higher value-add services.Defense segment saw an 86% YoY degrowth, while the Aerospace segment grew by 13% YoY.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's ability to execute its strong ₹23.5 billion order book and the growth in the Aerospace and Med-Tech segments to compensate for the volatile Defense revenue. The expansion in EBITDA margins despite lower revenue is a positive indicator of underlying operational strength.
Cyient DLM Q3 FY26: Revenue Drops 31.7% YoY, Normalized PAT Rises to INR 13.84 Cr
Cyient DLM reported a significant revenue decline of 31.7% YoY to INR 303.3 crores in Q3 FY26, primarily due to customer-side slowdowns and temporary one-off items. Despite the top-line pressure, normalized EBITDA margins improved by 207bps to 10.2%, and normalized PAT rose to INR 13.84 crores. A key positive is the strong YTD order intake of over INR 1,400 crores, representing an 87% YoY growth, which suggests a robust recovery pipeline. The company also maintained positive YTD Free Cash Flow of INR 754 million.
முக்கிய அம்சங்கள்
Revenue for Q3 FY26 stood at INR 303.3 crores, a decrease of 31.7% YoY.Normalized EBITDA margin expanded by 207bps YoY to 10.2%, reaching INR 30.94 crores.YTD order intake surged 87% YoY to over INR 1,400 crores, with INR 387 crores secured in Q3.Normalized PAT for the quarter was INR 13.84 crores (4.6% margin), while reported PAT was INR 11.2 crores.Year-to-date Free Cash Flow remains healthy at INR 754 million.
👀 கவனிக்க வேண்டியவை
Investors should focus on the strong order book growth and margin expansion as indicators of long-term health, while monitoring if the Q4 volume ramp-ups materialize to offset the current revenue decline. The stock may experience volatility due to the sharp YoY revenue drop, but the operational resilience and new program wins provide a defensive cushion.
Cyient DLM Shareholders Approve Appointment of Four Independent Directors with High Majority
Cyient DLM Limited has successfully passed four special resolutions via postal ballot for the appointment and re-appointment of Independent Directors. Dr. Ganesh Natarajan and Mr. Giridhar Aramane were appointed as new Independent Directors, receiving 98.72% and 99.99% support respectively. Dr. Vanitha Datla and Mr. Jehangir Ardeshir were re-appointed for second terms, both securing approximately 89.6% of the votes. The high voter turnout of nearly 80% reflects strong institutional and promoter engagement in the company's governance.
முக்கிய அம்சங்கள்
Appointment of Mr. Giridhar Aramane received near-unanimous approval with 99.99% votes in favorDr. Ganesh Natarajan's appointment as Independent Director approved with 98.72% majorityRe-appointments of Dr. Vanitha Datla and Mr. Jehangir Ardeshir passed with 89.60% and 89.61% supportTotal voting turnout reached 79.90% of outstanding shares, involving 63.4 million votesAll resolutions were passed as Special Resolutions through a remote e-voting process ending January 11, 2026
👀 கவனிக்க வேண்டியவை
Investors should take confidence in the company's strengthened board and high level of shareholder participation. No immediate portfolio changes are required as these are positive governance-related developments.
Cyient DLM: Postal Ballot for Director Appointments & Re-appointments
Cyient DLM Limited is seeking shareholder approval via postal ballot for the appointment and re-appointment of several Independent Directors. Dr. Ganesh Natarajan is proposed as a Non-Executive Independent Director for 3 years starting October 14, 2025. Dr. Vanitha Datla and Mr. Jehangir Ardeshir are proposed for re-appointment as Independent Directors for a second term of five years commencing December 12, 2025. Mr. Giridhar Aramane is proposed as Non-Executive Independent Director for 3 years starting November 26, 2025. The e-voting period is from December 13, 2025, to January 11, 2026, with results announced by January 12, 2026.
முக்கிய அம்சங்கள்
Appointment of Dr. Ganesh Natarajan (DIN:00176393) as Non-Executive, Independent Director effective 14 October, 2025 for 3 years.Re-Appointment of Dr. Vanitha Datla (DIN: 00480422) as Non-Executive, Independent Director for a second term of five years commencing from 12 December 2025.Re-Appointment of Mr. Jehangir Ardeshir (DIN: 02344835) as Non-Executive, Independent Director for a second term of five years commencing from 12 December 2025.Appointment of Mr. Giridhar Aramane (DIN: 00483130) as Non-Executive, Independent Director effective 26 November, 2025 for 3 years.Remote e-voting period: December 13, 2025 to January 11, 2026.
👀 கவனிக்க வேண்டியவை
Shareholders should review the Postal Ballot Notice and cast their votes electronically between December 13, 2025 and January 11, 2026. Pay attention to the profiles of the directors being appointed/re-appointed.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
